MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer. Yan D, Huelse JM, Kireev D, Tan Z, et al. J Clin Invest 2022 Jun 16. pii: 150517. doi: 10.1172/JCI150517.

Read + Share

Amedeo Smart

Independent Medical Education

Yan D, Huelse JM, Kireev D, Tan Z, et al. MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer. J Clin Invest 2022 Jun 16. pii: 150517. doi: 10.1172/JCI150517.
PMID: 35708914